Since entering January 2023, pharmaceutical companies have successively disclosed 2022 performance forecasts, it is reported that from January 13 to 15, a number of pharmaceutical companies have released performance forecasts, including Jiudian Pharmaceutical, Huahai Pharmaceutical, Tibet Pharmaceutical and many other pharmaceutical companies are pre-congratulatory
.
Among them, Huahai Pharmaceutical released a performance forecast on the evening of January 15, saying that after preliminary calculations by the financial department, the company's net profit attributable to the parent in 2022 is expected to be between 1.
12 billion yuan and 1.
2 billion yuan, an increase of about 130% to 146%
year-on-year.
At the same time, the net profit attributable to the parent after deduction is expected to be between 1.
1 billion yuan and 1.
18 billion yuan, an increase of about 1751%~1885%
year-on-year.
Jiudian Pharmaceutical also released a performance forecast on the evening of January 15, saying that it is expected that the net profit attributable to shareholders of listed companies in 2022 will be 263 million yuan ~ 273 million yuan, a year-on-year increase of 28.
77% ~ 33.
66%.
Tibet Pharmaceutical released the 2022 annual performance pre-increase announcement on the evening of January 13, saying that during the reporting period, the company is expected to achieve a net profit attributable to the parent of about 377 million, an increase of 168 million yuan compared with 209 million yuan in the same period of the previous year, a year-on-year increase of about 81%; The net profit was about 365 million, an increase of 298 million year-on-year, a year-on-year increase of about 447%.
In addition, Bide Pharma released the 2022 annual performance report on the evening of January 13, and the company achieved operating income of about 834 million yuan in 2022, an increase of 37.
55% over the same period last year; The net profit attributable to shareholders of the listed company was about 146 million yuan, an increase of 49.
43%
over the same period last year.
For the growth of performance, Huahai Pharmaceutical said that there are three main reasons for the change in the performance of this period, one is that with the promotion of national centralized procurement and the lifting of the US FDA ban, the increase in domestic market demand and the recovery of the US market have driven the production of preparations and the production of APIs, to a certain extent, diluting fixed costs, and the steady growth of sales of APIs and intermediate products and the slight increase in selling prices and other factors have affected the profit of the company's main business to increase
significantly 。 Second, with the sharp rise of the US dollar exchange rate in the current period, the company's exchange income increased, which affected the company's profit to a certain extent; The third is that the company comprehensively improves lean management to help enterprises reduce costs and increase efficiency
.
Jiudian Pharmaceutical said that during the reporting period, the company closely followed the reform of national pharmaceutical policies, accelerated the transformation of marketing models, built five major R&D systems, and promoted the integrated development
of various business units.
Important financial indicators such as main business income and net profit increased
significantly compared with the same period of the previous year.
The impact of non-recurring profit and loss on net profit during the reporting period is expected to be approximately $22.
00 million
.
It is reported that as of 9:43 on January 16, the stock price of Jiudian Pharmaceutical rose by 5.
55%, with 1.
7011 million shares traded, a transaction amount of 44.
4256 million yuan, and a turnover rate of 0.
80%.
Tibet Pharmaceutical announced that the company's net profit growth was mainly due to the increase in sales of the product neoactive, and the sales revenue accounted for about 88%
of the annual revenue.
The company said that from the perspective of overall business performance, the main business still has strong growth momentum, and the main business income for the whole year of 2022 has steadily increased, and its product neo-active elements continue to make efforts; From the perspective of production and sales supply, Xinhuo completed the renewal of medical insurance in 2021, and sales are expected to maintain strong growth
in the future.
Bede Pharmaceutical said that during the reporting period, the company's operating profit and total profit increased compared with the same period of the previous year, mainly due to the increase in the company's orders, sales growth, continuous optimization of product structure, net profit margin remained at a high level, and related profit indicators increased
compared with the previous year.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"share:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
